LNTH-2505
Glioblastoma
PreclinicalActive
Key Facts
About Lantheus Medical Imaging
Lantheus Medical Imaging is a leading public radiopharmaceutical company with a mission to 'Find, Fight, and Follow' disease through targeted diagnostic and therapeutic innovations. The company has achieved significant commercial success with products like PYLARIFY for prostate cancer imaging and is aggressively expanding its pipeline through strategic acquisitions and internal R&D into high-growth areas like radiotherapeutics and neurology diagnostics. Its strategy hinges on vertical integration, managing complex radiopharmaceutical logistics, and capitalizing on the growing precision medicine paradigm in nuclear medicine.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |
| BEA-17 | Beactica Therapeutics | Pre-clinical |